Physician profile
Jonathan Okman
NPI 1003227372
$99,103.69
in general payments reported to CMS, 2019-2025
28 companies · $17K in 2025
The $17K reported for 2025 was more than what 93% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $430 · 2020: $86.97 · 2021: $325 · 2022: $9,478 · 2023: $32K · 2024: $40K · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $69K · Food and Beverage: $9,927 · Travel and Lodging: $9,653 · Education: $453.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $68,750.00 |
| Food and Beverage | $9,927.17 |
| Travel and Lodging | $9,653.28 |
| Education | $452.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $83,900.76 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Janssen Scientific Affairs, LLC | $7,673.76 | 2022-2024 | Tremfya |
| Abbvie INC. | $1,865.72 | 2019-2025 | |
| Lilly USA, LLC | $1,203.54 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Ucb, INC. | $682.23 | 2019-2025 | Bimzelx |
| Pfizer INC. | $473.12 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $466.12 | 2020-2025 | |
| Sun Pharmaceutical Industries INC. | $451.09 | 2022-2025 | Absorica Ld, Winlevi, Ilumya |
| Genzyme Corporation | $353.75 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $349.12 | 2019-2025 | Dupixent |
| Amgen INC. | $311.99 | 2019-2025 | Otezla |
| Incyte Corporation | $260.08 | 2022-2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $219.17 | 2024 | Sotyktu |
| Leo Pharma INC. | $163.39 | 2022-2025 | Adbry, Anzupgo |
| Arcutis Biotherapeutics, INC. | $139.35 | 2024-2025 | Zoryve |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $127.60 | 2022-2024 | Spevigo |
| Dermavant Sciences, INC. | $84.00 | 2023-2024 | Vtama |
| Revance Therapeutics, INC. | $75.33 | 2024 | Daxxify |
| Kyowa Kirin, INC. | $69.22 | 2022-2023 | Poteligeo |
| Galderma Laboratories, L.P. | $52.92 | 2025 | Nemluvio |
| Strata Skin Sciences, INC. | $36.60 | 2025 | Xtrac |
| Biofrontera INC. | $28.37 | 2025 | |
| Merz North America, INC. | $24.45 | 2019 | |
| Dermira, INC. | $23.72 | 2019 | |
| Dusa Pharmaceuticals, INC. | $22.56 | 2019 | |
| Botanix Sb INC | $18.32 | 2025 | Sofdra |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $17.59 | 2021 | |
| Organon LLC | $9.82 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Okman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.